Preference for daily (1HP) vs. weekly (3HP) isoniazid-rifapentine among people living with HIV in Uganda

IJTLD OPEN Pub Date : 2024-02-01 DOI:10.5588/ijtldopen.23.0283

A. Musinguzi, H. E. Aschmann, J. Kadota, J. Nakimuli, F. Welishe, J. Kakeeto, C. Namale, L. Akello, A. Nakitende, C. Berger, A. Katamba, J. Tumuhamye, N. Kiwanuka, D. Dowdy, A. Cattamanchi, F. Semitala

{"title":"Preference for daily (1HP) vs. weekly (3HP) isoniazid-rifapentine among people living with HIV in Uganda","authors":"A. Musinguzi, H. E. Aschmann, J. Kadota, J. Nakimuli, F. Welishe, J. Kakeeto, C. Namale, L. Akello, A. Nakitende, C. Berger, A. Katamba, J. Tumuhamye, N. Kiwanuka, D. Dowdy, A. Cattamanchi, F. Semitala","doi":"10.5588/ijtldopen.23.0283","DOIUrl":null,"url":null,"abstract":"BACKGROUNDBoth 1 month of daily (1HP) and 3 months of weekly (3HP) isoniazid-rifapentine are recommended as short-course regimens for TB prevention among people living with HIV (PLHIV). We aimed to assess acceptability and preferences for 1HP\n vs. 3HP among PLHIV.METHODSIn a cross-sectional survey among PLHIV at an HIV clinic in Kampala, Uganda, participants were randomly assigned to a hypothetical scenario of receiving 1HP or 3HP. Participants rated their level of perceived\n intention and confidence to complete treatment using a 0–10 Likert scale, and chose between 1HP and 3HP.RESULTSAmong 429 respondents (median age: 43 years, 71% female, median time on ART: 10 years), intention and confidence were rated\n high for both regimens. Intention to complete treatment was rated at least 7/10 by 92% (189/206 randomized to 1HP) and 93% (207/223 randomized to 3HP). Respectively 86% (178/206) and 93% (208/223) expressed high confidence to complete treatment. Overall, 81% (348/429) preferred 3HP over 1HP.CONCLUSIONSBoth\n 1HP and 3HP were highly acceptable regimens, with 3HP preferred by most PLHIV. Weekly, rather than daily, dosing appears preferable to shorter duration of treatment, which should inform scale-up and further development of short-course regimens for TB prevention.","PeriodicalId":516613,"journal":{"name":"IJTLD OPEN","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJTLD OPEN","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5588/ijtldopen.23.0283","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

BACKGROUNDBoth 1 month of daily (1HP) and 3 months of weekly (3HP) isoniazid-rifapentine are recommended as short-course regimens for TB prevention among people living with HIV (PLHIV). We aimed to assess acceptability and preferences for 1HP vs. 3HP among PLHIV.METHODSIn a cross-sectional survey among PLHIV at an HIV clinic in Kampala, Uganda, participants were randomly assigned to a hypothetical scenario of receiving 1HP or 3HP. Participants rated their level of perceived intention and confidence to complete treatment using a 0–10 Likert scale, and chose between 1HP and 3HP.RESULTSAmong 429 respondents (median age: 43 years, 71% female, median time on ART: 10 years), intention and confidence were rated high for both regimens. Intention to complete treatment was rated at least 7/10 by 92% (189/206 randomized to 1HP) and 93% (207/223 randomized to 3HP). Respectively 86% (178/206) and 93% (208/223) expressed high confidence to complete treatment. Overall, 81% (348/429) preferred 3HP over 1HP.CONCLUSIONSBoth 1HP and 3HP were highly acceptable regimens, with 3HP preferred by most PLHIV. Weekly, rather than daily, dosing appears preferable to shorter duration of treatment, which should inform scale-up and further development of short-course regimens for TB prevention.

查看原文本刊更多论文

乌干达艾滋病毒感染者对每日（1HP）与每周（3HP）服用异烟肼-利福喷丁的偏好

背景建议将每天服用 1 个月（1HP）异烟肼-利福喷丁和每周服用 3 个月（3HP）异烟肼-利福喷丁作为艾滋病病毒感染者（PLHIV）预防结核病的短程治疗方案。我们旨在评估 PLHIV 对 1HP 与 3HP 的接受度和偏好。方法在乌干达坎帕拉一家 HIV 诊所对 PLHIV 进行横断面调查，参与者被随机分配到接受 1HP 或 3HP 的假设情景中。结果在 429 名受访者（中位数年龄：43 岁，71% 为女性，中位数接受抗逆转录病毒疗法时间：10 年）中，两种治疗方案的意向和信心都很高。92%的受访者（189/206 人随机选择 1HP 方案）和 93%的受访者（207/223 人随机选择 3HP 方案）对完成治疗的意向评分至少为 7/10。分别有 86%（178/206）和 93%（208/223）的人对完成治疗表示很有信心。总体而言，81%的患者（348/429）更倾向于 3HP 而非 1HP。每周给药而不是每天给药似乎更有利于缩短疗程，这应为结核病预防短疗程方案的推广和进一步开发提供参考。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

IJTLD OPEN

自引率

0.00%

发文量